Ono Licenses Japanese Rights To Hyperparathoid Drug Candidate
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Ono Pharmaceutical agreed to pay ¥1 billion ($13 million) upfront for the exclusive rights to develop and market KAI-4169 in Japan